Company intelligence / Profile preview
Scancell Holdings
Nottingham, Nottinghamshire, United Kingdomscancell.co.uk ↗
- Ownership
- Public · SCLP
- Employees
- ~45
- Development stage
- Other
01
Overview
Scancell Holdings is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer and infectious diseases. The company utilizes four proprietary technology platforms: ImmunoBody, Moditope, AvidiMab, and GlyMab. Its lead program, SCIB1, is a DNA vaccine currently in Phase 2 clinical trials for the treatment of metastatic melanoma. Scancell's Moditope platform targets stress-induced post-translational modifications to stimulate potent T cell responses against solid tumors. The company is also developing a pipeline of monoclonal antibodies targeting tumor-associated glycans through its GlyMab platform.
- Therapeutic areas
- Oncology
- Modalities
- DNA vaccineMonoclonal antibodyPeptidesRecombinant protein
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
GenmabCancer Research UKUniversity of Nottingham
04
Financials
- Market cap
- $134.8M
- Total revenue
- $0
- Enterprise value
- $150.6M
Beyond the preview
Go deeper on Scancell Holdings.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Scancell Holdings.